Peptide Based Metabolic Disorders Therapeutics Market, By Drug (Liraglutide, Exenatide and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2034

Report Code: PMI483521 | Publish Date: November 2023 | No. of Pages: 168

Global Peptide Based Metabolic Disorders Therapeutics Market Companies

  • AstraZeneca PLC
  • Teva Pharmaceutical Industries Ltd.
  • PolyPeptide Group
  • Novo Nordisk A/S
  • Merck & Co., Inc.
  • Ipsen S.A
  • Eli Lilly Company
  • CordenPharma International
  • Bachem Holding AG.

Recent News:

  • According to the research article by ResearchGate, The progressive development of peptides from reaction vessels to life-saving drugs via rigorous preclinical and clinical assessments is fascinating. With the advancement of peptide chemistry techniques including ligation chemistry, recombinant synthesis, solid- and solution-phase synthesis using microwave irradiation, amalgamation with synthetic tools like metal catalysis, and ligation chemistry, peptide therapies have gained impetus.